MedTrace Logo

Post-Market BTVA Registry

NCT03318406 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-01-28

No results posted yet for this study

Summary

Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is a retrospective and prospective, observational, multi-center, post-market registry of patients prescribed InterVapor. The primary objective of the Registry is to describe the long-term impact of InterVapor treatment on patient quality of life (QOL) in a real-world setting. After InterVapor treatment, patients will be followed for 5 years as per the standard of care and safety and efficacy data (quality of life, pulmonary function, exercise capacity) collected as part of the registry.

Conditions

  • Emphysema or COPD

Interventions

DEVICE

Bronchoscopic Thermal Vapor Ablation

Bronchoscopic vapor delivery to airway segment(s) targeted for treatment

Sponsors & Collaborators

  • Uptake Medical Technology, Inc.

    lead INDUSTRY

Principal Investigators

  • Felix Herth, MD, PhD · Thoraxklinik University of Heidelberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-22
Primary Completion
2027-12-01
Completion
2030-12-01

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03318406 on ClinicalTrials.gov